Rifat A Chaudry1, Mark Rosenthal2, Andrew Bush3, Suzanne Crowley4. 1. Department of Paediatrics, St George's Hospital, London, UK Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK. 2. Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK. 3. Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK Department of Paediatrics, Imperial College, London, UK. 4. Department of Paediatrics, St George's Hospital, London, UK.
Abstract
BACKGROUND: Asthma and airway hyper-responsiveness are reportedly more common in children with sickle cell disease (SCD). AIM: To determine airway responsiveness, airway inflammation and clinical features of asthma in SCD. METHODS: A prospective, single-centre study of 50 SCD children without overt pulmonary vascular disease and 50 controls. Exhaled nitric oxide (FeNO) and total serum IgE were measured and spirometry and methacholine challenge were performed. The methacholine dose-response slope (DRS) was calculated. RESULTS: Doctor diagnosis of asthma was made in 7 (14%) SCD versus 12 (24%) control subjects (p=0.203). FeNO levels were similar in SCD and controls (p=0.250), and were higher in those with atopy and an asthma diagnosis (OR 4.33, 95% CI 1.7 to 11.1; p<0.05). zFEV1 (p=0.002) and zFEV1/FVC (p=0.003) but not zFVC (p=0.098) were lower in SCD versus controls. DRS was higher in those with asthma (p=0.006) but not in SCD versus controls (p=0.403). DRS correlated with FeNO and blood eosinophil count in controls but not SCD. In SCD, DRS was higher in those admitted to hospital with respiratory symptoms (n=27) versus those never admitted (n=23) (p=0.046). DRS was similar in those with at least one acute chest syndrome episode (n=12) versus those with none (n=35) (p=0.247). CONCLUSIONS: SCD children have airflow obstruction despite having minimal evidence of pulmonary vascular disease. Airflow obstruction is not associated with increased methacholine sensitivity or eosinophilic inflammation, at least as judged by FeNO. Airflow obstruction in SCD does not appear to be related to childhood eosinophilic asthma, but its pathophysiology remains ill understood. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND:Asthma and airway hyper-responsiveness are reportedly more common in children with sickle cell disease (SCD). AIM: To determine airway responsiveness, airway inflammation and clinical features of asthma in SCD. METHODS: A prospective, single-centre study of 50 SCD children without overt pulmonary vascular disease and 50 controls. Exhaled nitric oxide (FeNO) and total serum IgE were measured and spirometry and methacholine challenge were performed. The methacholine dose-response slope (DRS) was calculated. RESULTS: Doctor diagnosis of asthma was made in 7 (14%) SCD versus 12 (24%) control subjects (p=0.203). FeNO levels were similar in SCD and controls (p=0.250), and were higher in those with atopy and an asthma diagnosis (OR 4.33, 95% CI 1.7 to 11.1; p<0.05). zFEV1 (p=0.002) and zFEV1/FVC (p=0.003) but not zFVC (p=0.098) were lower in SCD versus controls. DRS was higher in those with asthma (p=0.006) but not in SCD versus controls (p=0.403). DRS correlated with FeNO and blood eosinophil count in controls but not SCD. In SCD, DRS was higher in those admitted to hospital with respiratory symptoms (n=27) versus those never admitted (n=23) (p=0.046). DRS was similar in those with at least one acute chest syndrome episode (n=12) versus those with none (n=35) (p=0.247). CONCLUSIONS: SCD children have airflow obstruction despite having minimal evidence of pulmonary vascular disease. Airflow obstruction is not associated with increased methacholine sensitivity or eosinophilic inflammation, at least as judged by FeNO. Airflow obstruction in SCD does not appear to be related to childhood eosinophilic asthma, but its pathophysiology remains ill understood. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Biree Andemariam; Alexander J Adami; Anurag Singh; Jeffrey T McNamara; Eric R Secor; Linda A Guernsey; Roger S Thrall Journal: Transl Res Date: 2015-03-16 Impact factor: 7.012
Authors: Aravind Yadav; Fernando F Corrales-Medina; James M Stark; S Shahrukh Hashmi; Mary P Carroll; Keely G Smith; Kristen M Meulmester; Deborah L Brown; Cindy Jon; Ricardo A Mosquera Journal: Pediatr Allergy Immunol Pulmonol Date: 2015-09-01 Impact factor: 1.349
Authors: Robyn T Cohen; Robert C Strunk; Mark Rodeghier; Carol L Rosen; Fenella Jane Kirkham; Jane Kirkby; Michael R DeBaun Journal: Ann Am Thorac Soc Date: 2016-08
Authors: Jeffrey Glassberg; Caterina Minnitti; Caroline Cromwell; Lawrence Cytryn; Thomas Kraus; Gwen S Skloot; Jason T Connor; Adeeb H Rahman; William J Meurer Journal: Am J Hematol Date: 2017-06-05 Impact factor: 10.047
Authors: Robyn T Cohen; Mark Rodeghier; Fenella J Kirkham; Carol L Rosen; Jane Kirkby; Michael R DeBaun; Robert C Strunk Journal: J Allergy Clin Immunol Date: 2016-08-09 Impact factor: 10.793
Authors: Shaina M Willen; Mark Rodeghier; Robert C Strunk; Carol L Rosen; Fenella J Kirkham; Joshua J Field; Michael R DeBaun; Robyn T Cohen Journal: Am J Respir Crit Care Med Date: 2017-06-01 Impact factor: 21.405
Authors: Alan Lunt; Na'eem Ahmed; Gerrard F Rafferty; Moira Dick; David Rees; Sue Height; Swee Lay Thein; Anne Greenough Journal: Pediatr Res Date: 2015-10-22 Impact factor: 3.756